3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
2
Phase 4
1
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
14
Colorectal Neoplasms
9
Neoplasm Metastasis
3
Leukemia, Myeloid, Acute
3
Sarcoma, Ewing
2
Rectal Neoplasms
2
Myelodysplastic Syndromes
2
Liver Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Wilms Tumor
1
Thrombocytosis
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Pretreated Metastatic Colorectal Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Multiple Myeloma
1
Metastatic Solid Malignancies
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Imatinib Mesylate
12
Sunitinib
4
Leucovorin
3
ripretinib
2
nilotinib
2
avapritinib
2
Oxaliplatin
2
Irinotecan
2
Ipilimumab
2
Fluorouracil
2
CTLA-4 Antigen
2
umbralisib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
ribociclib
1
repaglinide
1
regorafenib
1
pexidartinib
1
olverembatinib
1
binimetinib
1
alvocidib
1
Thalidomide
1
TH 302
1
TAS-116
1
Pharmacogenomic Testing
1
OSI 930
1
Midazolam
1
IDRX-42
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gastrointestinal Stromal Tumors
×
regorafenib
×
Clear all
NCT02164240
2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1
Completed
14 enrolled
8 charts